Grant Award Details
- Identify a new noncoding RNA chemical entity, TY4 or modified TY4, that is effective in treating heart failure with preserved ejection fraction (HFpEF) in rodent models.
Grant Application Details
- New noncoding RNA chemical entity for heart failure with preserved ejection fraction.
Modified synthetic noncoding RNA molecule
Heart failure with preserved ejection fraction
Major Proposed Activities
- Lead optimization
- Perform extensive preclinical testing and select a therapeutic candidate.
- Develop and test preliminary potency assays based on mechanistic insights.
- Demonstration of injury-modifying bioactivity in a clinically-relevant human progenitor cell population.
- Optimize formulation and dosing for intravenous delivery, assessing biodistribution.
- Optimize formulation and dosing for oral delivery. Plus Activity 7: Regulatory planning.
The target indication is heart failure with preserved ejection fraction (HFpEF), a highly lethal disease refractory to medical intervention. HFpEF is increasing in prevalence, and now accounts for most hospital admissions for heart failure in California. HFpEF disproportionately afflicts disadvantaged populations (women, Blacks and Latinos, and the elderly). Because the therapeutic candidate is universally applicable, the societal benefits of success here are expected to be profound.